Background: Faecal microbiota transplantation [FMT] has been investigated as a potential treatment for inflammatory bowel disease [IBD]. We thus performed a systematic review and meta-analysis assessing the effectiveness and safety of FMT in IBD. Methods: A systematic review was conducted until January 2017. Studies were excluded if patients had co-infection or data were pooled across disease subtypes (ulcerative colitis [UC], Crohn's disease [CD], pouchitis). Clinical remission was established as the primary outcome. Pooled effect sizes and 95% confidence intervals were obtained using the random effects model. Conclusions: FMT appears effective in UC remission induction, but long-term durability and safety remain unclear. Additional well-designed controlled studies of FMT in IBD are needed, especially in CD and pouchitis.
Introduction
Faecal microbiota transplantation [FMT] has revolutionised the field of microbial therapeutics. It has proven extremely effective in the treatment of Clostridium difficile infection [CDI], 1, 2 and is considered to have potential in other conditions where disturbances in the enteric microbiota are implicated in disease pathogenesis, such as the inflammatory bowel diseases [IBD] . 3 Although FMT is a simple therapy in practice that was first described in Western medical literature over 50 years ago, 4 and proposed as a treatment strategy for IBD over 25 years ago, 5 it is only in recent years that there has been an exponential growth in patient, media, and research interest. 6 The initial systematic review on the role of FMT in IBD published in 2012 consisted of only nine retrospective reports, deemed of insufficient quality to perform meta-analysis. 7 Within 2 years, an updated systematic review identified 18 studies, including nine cohort studies of FMT in IBD on which a meta-analysis was performed. 8 Since then, the number of available studies has again more than doubled, including the publication of the first four randomised controlled trials [RCTs] of FMT in ulcerative colitis [UC]. [9] [10] [11] [12] In this latest systematic review and meta-analysis, we summarise the available literature and evaluate the efficacy of FMT in the various IBD subtypes of UC, Crohn's disease [CD] , and pouchitis, by performing meta-analyses on the associated prospective studies.
Methods

Search strategy 2.3. Data extraction
References were imported into a bibliographic database [Microsoft Excel 2015] . Two authors [SP, RP] independently reviewed all articles, initially by title and abstract, then by full text review where relevant, to determine eligibility. Duplicate studies/data were removed manually; when multiple publications related to the same patient group, the most complete data set was included. Eligible studies were categorised based on FMT indication. Data related to the study design and characteristics, treatment groups, and outcome measures were recorded. Where there was disagreement on study eligibility or data extraction, consensus was achieved through discussion [SP, RP, NCR].
Study quality assessment
For eligible cohort studies, the methodological quality was assessed using the Newcastle-Ottawa Scale [NOS] 16 on the standard 9-point scale. Included RCTs were assessed using the Cochrane risk of bias score 17 incorporating random sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting.
Statistical analysis
Descriptive statistics were performed on data extracted from all included studies. The efficacy of treatment [clinical remission and/or response] was compared across studies per IBD subtype. For disease subtypes where three or more cohort or RCT studies were included, a meta-analysis was performed. The pooled effect sizes, as well as 95% confidence intervals [CIs] , were calculated using both fixed and random effects models. However, the random effects model was the preferred option as it assumes that there is a distribution of true effect sizes rather than one true effect, and it assigns a more balanced weight to each study. For meta-analyses including cohort studies, the effect size refers to the pooled estimate proportion of patients that achieved efficacy. For meta-analyses including RCTs, pooled odd ratios [P-ORs] were calculated by weighting individual ORs by the inverse of their variance. p-values < 0.05 were considered significant. Heterogeneity was assessed using Cochran´s Q test [p-value < 0.10 is indicative of heterogeneity] and Higgins´ test [I 2 ] [low heterogeneity: < 25%, moderate heterogeneity: 25-75%, and high heterogeneity: > 75%]. 18 
Results
Study characteristics
A total of 6806 articles were identified in the search, which included 261 internal and external duplicates [ Figure 1 ]. Titles and abstracts of 6545 articles were screened and only 109 were deemed potentially eligible, of which 107 were available for review. A total of 53 articles or abstracts of FMT in IBD were deemed to satisfy the study selection criteria and were included in the final analysis, of which three included more than one IBD subtype. This included 41 articles or abstracts assessing FMT in UC and reporting on 555 UC patients, 11 in CD reporting on 83 CD patients, and four in pouchitis reporting on 23 patients.
Study quality
The methodological quality of the included cohort studies and RCTs are outlined in the Appendix [Tables A2, A3 , available as Supplementary data at ECCO-JCC online]. Only four cohort studies included a control group, with a mean NOS score of 5 [range 3 to 9] out of 9. The risk of bias in the included randomized trials was low [Costello et al., 2017, 12 presented in abstract form but yet to undergo full publication peer review]. All significant results obtained through the meta-analyses remained significant in sensitivity analyses, inferring statistical robustness.
Ulcerative colitis
A total of 41 studies were identified assessing FMT in UC (nine case reports, five case series, 24 prospective cohort studies [20 uncontrolled Figure A1 , available as Supplementary data at ECCO-JCC online]; a moderate level of heterogeneity [Cochran's Q, p = 0.001; I 2 = 58%] and no publication bias was observed in this meta-analysis [ Table A5 ].
Meta-analysis including four RCTs of FMT in UC [ Figure 3 ], which comprised a total of 140 FMT-treated individuals, showed that FMT was significantly associated with clinical remission in these patients [P-OR = 2.89, 95% CI = 1. between FMT and clinical response in these patients when the RCT by Rossen et al. 10 was removed showed a higher P-OR of 3.39 [95% CI = 1.90-6.04, p = < 0.001; Cochran's Q, p = 0.442; I 2 = 0%] [ Figure  A4 , available as Supplementary data at ECCO-JCC online].
Crohn's disease
Eleven studies in CD [four case reports, seven prospective uncontrolled cohort studies] reporting on 83 CD patients were included [ Table 4 ]. Overall 50.5% [42/83] of CD patients achieved clinical remission during follow-up. Among the six cohort studies included in the meta-analysis [ Figure 4 ], comprising 71 individuals, the pooled proportion of CD patients that achieved clinical remission was 52% [95% CI = 31-72%] with a moderate risk of heterogeneity [Cochran's Q, p = 0.063; I 2 = 52%]; however, publications bias was observed in this meta-analysis [ Table A5 ]. A meta-analysis including four cohort studies [ Figure A5 , available as Supplementary data at ECCO-JCC online], which comprised 59 individuals, showed that the pooled estimate proportion of patients that achieved clinical response was 63% [95% CI = 30-88%]. Moderate heterogeneity was observed in this meta-analysis [Cochran's Q, p = 0.016, I 2 = 71%]; no publication bias was detected [ Table A5 ].
Pouchitis
Three prospective uncontrolled cohort studies and one case report assessing FMT in pouchitis were identified [ 65 We did not perform a pouchitis meta-analysis as only three small cohort studies were identified which had differing endpoints and conflicting outcomes.
Endoscopic data
Specific endoscopic outcomes were reported in the four RCTs and six of the 24 cohort studies of FMT in UC [ Table 2 ]. Accounting for differing definitions of endoscopic outcomes, endoscopic remission or endoscopic response rates of 24-55% with allogeneic FMT vs 5-17% with control [placebo or autologous FMT] [mean difference 26.3% ± 9.9, p-value: 0.057] were noted in the RCTs involving multiple lower gastrointestinal FMT infusions, 9, 11, 12 whereas no difference was noted in endoscopic response between allogenic or autologous FMT administered by two nasoduodenal infusions [35% vs 36%] 10 [ Table 3 ]. Only one study in CD reported endoscopic outcomes, 42 with none of six patients achieving endoscopic remission. In the one pouchitis study that reported endoscopic outcomes, all five patients had an endoscopic response and one patient [20%] achieved endoscopic remission after 1-7 FMT infusions. 65 
Histologic data
Only a small number of studies in UC reported histologic outcomes. Post hoc analysis of one RCT identified that 7/38 patients in the FMT arm and 1/37 in the placebo arm achieved histologic remission. 9 Only two of the 24 identified cohort studies of FMT in UC reported histologic data. 36, 38 Only one case report of FMT in CD provided histologic outcomes. 57 In the one pouchitis study that reported histologic outcomes, none of five patients achieved a PDAI histologic subscore of 0. 65 
Paediatric vs adult populations
Subgroup analyses were performed for a number of variables thought to be of importance [ Table A6, available 
FMT methodology
The included studies varied substantially in FMT infusion methodology/protocol, including route of administration, number and frequency of infusions, dosage of stool per infusion, preparation of inoculum [ 
Safety
The majority of studies did not report major adverse events or serious adverse events that were deemed clinically related to FMT therapy. Most reported adverse events were transient minor gastrointestinal complaints [bloating, diarrhoea, flatulence, abdominal pain/cramping, borborygmus] and/or fever. [31] [32] [33] [34] [35] 44, [46] [47] [48] 52, 54, [58] [59] [60] [61] 63 The lack of a control arm in most of the studies makes it difficult to determine to what degree symptoms are specifically attributable to FMT. Nasogastric FMT infusion was associated with aspiration pneumonia in one study, 42 prompting a switch to lower gastrointestinal [GI] administration. A few reports of disease worsening 40, 49, 55 were identified, including one of cytomegalovirus [CMV] colitis in a patient who self-administered unscreened FMT. 21 One death due to toxic megacolon and sepsis was reported. 53 The RCTs found no difference between FMT and control arms in terms of minor or serious adverse events or disease worsening [ Table 6 ], though it must be noted that these studies were not powered to specifically assess for safety.
Microbiological analyses
Microbiota analysis was performed in 17/41 UC, 4/11 CD, and 3/4 pouchitis studies [ 33, 63, 66, 67 A range of studies commented on recipient microbiota changes after FMT, with increased α-diversity or richness 9, 11, 38, 42, 48, 50, 61, 66 and a shift towards the donor profile, which in some cases was associated with colonisation by donor-derived taxa, though this was reported in patients both with clinical benefit 10, 26, 32, 35, 57, 60, 65 and without improvement. 33, 36 Some studies did report that the increase in recipient microbial diversity after FMT was greater in responders relative to non-responders. 11, 42, 61, 66 In particular, the study by Paramsothy et al. 11, 66 found that recipient microbial diversity at baseline predicted response to FMT, that microbial diversity increased with FMT, and that this persisted for 8 weeks following FMT. In this study, the multi-donor FMT batches used for the FMT infusions had substantially greater microbial diversity relative to the individual donors. A correlation between increased donor microbial diversity and therapeutic success of FMT in UC has been identified in some studies 42, 68 but not others. 51 In the RCT by Moayeddi et al., 9 there was a trend towards a difference in recipient outcomes based on particular donor, with improved outcomes noted in patients receiving infusions derived from donor B [p = 0.06]. A variety of taxa were reported to be associated with both FMT in IBD in general, and more specifically with therapeutic outcomes in IBD patients, across the identified studies.
Discussion
This paper represents an up-to-date systematic review and metaanalysis of FMT in IBD, incorporating both full text and abstract studies. There are almost three times as many studies included in this paper compared with previous systematic reviews and/or metaanalyses on the topic, 7, 8, 69, 70 illustrating the rapid growth in global research interest and activity with regards to FMT for IBD, including the first randomised trials of FMT in IBD. [9] [10] [11] [12] However, the overall quality of the studies remains low, primarily consisting of either case reports/series or small cohort studies of limited duration. Additionally, there remains considerable heterogeneity among the studies in terms of design, with conflicting treatment protocols [route of administration, number and frequency of infusions, antibiotic pre-treatment, bowel lavage] along with differing and often highly variable and/or poorly defined efficacy endpoints.
FMT in UC appears very promising, especially with multiple infusions administered via the lower gastrointestinal tract. An earlier meta-analysis, 8 Figure  3 ]. Further sensitivity analyses showed that removal of the smallest study 10 [which used only two infusions and administered them via an upper gastrointestinal infusion, as opposed to the other studies] resulted in an even more highly significant association between FMT and clinical remission in UC patients [P-OR of 4.05, 95% CI = 2.08-7.89, p = < 0.001] [ Figure A3 ]. This, along with subgroup analyses of the UC cohort studies, suggests that multiple infusions [and possibly lower gastrointestinal administration] increases the likelihood of remission in UC patients treated with FMT, though the precise number required varied substantially between studies, remains to be defined, and likely is donor-and recipient-dependent.
Regarding the role of FMT in CD, the pooled proportion of patients that achieved clinical remission presented in the current meta-analysis [52%] is slightly lower than the figure reported in the previous meta-analysis 8 [pooled proportion = 60.5%, 95% CI = 28.4%-85.6%]. As previously highlighted by these authors, however, the CD results should be interpreted with caution, as the confidence intervals remain wide and the pooled effect size may be inflated due to the variability of methodology among individual studies and the still limited data. This is further supported by the publications bias observed in the current meta-analysis on clinical remission and FMT in CD patients. Furthermore, it is known that clinical remission does not correlate with endoscopic outcomes in CD. Of note, in the only CD cohort study to report endoscopic outcomes, no patient experienced endoscopic remission. 42 There remain major limitations in the available literature of this developing field. There are insufficient data to support FMT for other indications besides CDI, 71, 72 with no randomised trials published or presented to date outside UC. Even within UC, the existing studies are relatively small in size [largest 81 patients], and where FMT would be best placed in the therapeutic algorithm is unclear given the growing number of biologics 73 and emerging targeted small molecule therapies. 74, 75 Long-term follow-up data regarding FMT efficacy/durability and safety in IBD are lacking. The available data suggest that disease relapse will invariably occur [though the durability and impact of number of infusions are poorly defined] and some form of maintenance therapy is required. However, almost all studies performed to date have assessed the role of FMT in remission induction for IBD, with a paucity of literature on the potential of FMT as a maintenance therapy 38 once remission is established. The safety data from the available literature are reassuring though limited by study size and follow-up period. There have been reports from the FMT in IBD and CDI co-infection literature, of disease flare following FMT. 76, 77 However, these must be considered in the context of an absence of a control arm [to account for gastrointestinal symptoms after FMT in non-IBD patients], difficulty in distinguishing colitis symptoms attributable to IBD as opposed to CDI, along with variable endoscopic mucosal activity assessment. In this context, Fischer et al. 77 reported improvement in clinician assessment of IBD activity after FMT for CDI in 31/67 [46%] and worsening in 12/67 [18%]. Additionally, there are few well-conducted microbiological studies on the effect of FMT on the intestinal microbiota in IBD. These are clearly required if we are to better understand the underlying mechanism of action and microbial predictors of therapeutic outcome, both beneficial and detrimental. Most studies to date have included small numbers of patients and focused primarily on microbial composition and not functional/metabolic consequences. Taxanomic changes identified to date associated with FMT and therapeutic benefit, are variable and inconsistent [ Table A7 ]. There exist inherent differences among donors, regardless of whether they are related or unrelated/ anonymous, and the clinical and microbiological factors that are of importance in donor outcomes remain largely undefined.
The American Gastroenterological Association [AGA] has recently set up an FMT registry [http://www.gastro.org/patient-care/ registries-studies/fmt-registry] to help characterise long-term outcomes of FMT [though this is primarily directed towards Clostridium difficile infection], and there are many new studies of FMT in IBD in progress [clinicaltrials.gov] that will hopefully address these issues. Future directions should also include more specific and targeted allied microbiological studies to try to identify donor and recipient factors of importance, which may potentially facilitate progress to donor-recipient matching, and ultimately defined microbial consortia based on recipient phenotype, along with ongoing development of capsule therapy with directed small bowel or colonic release.
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